Boston Scientific delivered a strong first quarter with robust revenue growth exceeding guidance, driven by solid performance across its key segments and regions. The company also saw a significant increase in GAAP net income and EPS compared to the prior year, alongside strategic advancements in clinical trials and product approvals.
Reported net sales of $5.203 billion, an increase of 11.6% on a reported basis, exceeding the company's guidance range of 10.5% to 12.0%.
positiveGAAP net income attributable to common stockholders was $1.341 billion, or $0.90 per share, a significant increase from $674 million or $0.45 per share in the prior year.
positiveCardiovascular segment net sales grew 13.5% reported and 11.2% operationally/organically.
positiveAPAC region net sales grew 14.7% reported and 12.0% operationally.
positiveAnnounced positive clinical trial results for WATCHMAN FLX and FARAPULSE PFA, and received regulatory approvals in China and FDA clearance for new systems.
positiveOperational net sales growth for Urology was only 0.5% compared to 2.1% reported growth, indicating a slight impact from foreign currency fluctuations.
attentionEMEA region operational net sales growth was 1.2% compared to 10.1% reported growth, significantly impacted by foreign currency fluctuations.
attentionLACA region operational net sales growth was 12.0% compared to 19.0% reported growth, indicating a notable impact from foreign currency fluctuations.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Endoscopy | N/A | — | — | — | +6.8% |
Urology | N/A | — | — | — | +0.5% |
Neuromodulation | N/A | — | — | — | +15.4% |
MedSurg | N/A | — | — | — | +5.7% |
Cardiovascular | N/A | — | — | — | +11.2% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Our global team and the strength of our category leadership strategy enabled us to deliver solid results this quarter.
We remain focused on executing our long-term strategy and advancing our differentiated pipeline to drive meaningful impact for patients, physicians and hospital systems.
Achieved strong net sales growth across key segments like Cardiovascular and Neuromodulation.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.